Evidence map›Paper›PMID 25102225›Full record

ArticleJournal of human hypertension2015

The -665 C>T polymorphism in the eNOS gene predicts cardiovascular mortality and morbidity in white Europeans.

L Olivi, Y M Gu, E Salvi, Y P Liu, L Thijs, D Velayutham, Y Jin, L Jacobs, F D'Avila, T Petit and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of human hypertension, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

L Olivi1] Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium [2] Department of Health Sciences and Graduate School of Nephrology, University of Milan, Milan, Italy.
Y M GuStudies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
E SalviDepartment of Health Sciences and Graduate School of Nephrology, University of Milan, Milan, Italy.
Y P LiuStudies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
L ThijsStudies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
D Velayutham1] Department of Health Sciences and Graduate School of Nephrology, University of Milan, Milan, Italy [2] Genomic and Bioinformatics Units, Filarete Foundation, Milan, Italy.
Y JinStudies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
L JacobsStudies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
F D'Avila1] Department of Health Sciences and Graduate School of Nephrology, University of Milan, Milan, Italy [2] Genomic and Bioinformatics Units, Filarete Foundation, Milan, Italy.
T PetitStudies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
M Barcella1] Department of Health Sciences and Graduate School of Nephrology, University of Milan, Milan, Italy [2] Genomic and Bioinformatics Units, Filarete Foundation, Milan, Italy.
C LanzaniDepartment of Nephrology and Dialysis, Universitá Vita Salute San Raffaele, Milan, Italy.
T KuznetsovaStudies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
P ManuntaDepartment of Nephrology and Dialysis, Universitá Vita Salute San Raffaele, Milan, Italy.
C Barlassina1] Department of Health Sciences and Graduate School of Nephrology, University of Milan, Milan, Italy [2] Genomic and Bioinformatics Units, Filarete Foundation, Milan, Italy.
D Cusi1] Department of Health Sciences and Graduate School of Nephrology, University of Milan, Milan, Italy [2] Genomic and Bioinformatics Units, Filarete Foundation, Milan, Italy.
J A Staessen1] Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium [2] Department of Epidemiology, Maastricht University, Maastricht, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We recently identified rs3918226 as a hypertension susceptibility locus (-665 C>T), TT homozygosity being associated with higher hypertension risk. T compared with C allele transfected cells had lower endothelial nitric oxide synthase (eNOS) expression. In the family-based Flemish Study on Environment, Genes and Health Outcomes (50.9% women; mean age 40.3 years), we investigated whether 32 TT homozygotes had worse outcomes than 2787 C allele carriers. Over 15 years (median), total and cardiovascular mortality and cardiovascular and coronary events amounted to 269 (9.5%), 98 (3.5%), 247 (8.8%) and 120 (4.3%), respectively. While accounting for family clusters, the hazard ratios associated with TT homozygosity were 4.11 (P=0.0052) for cardiovascular mortality (4 deaths), 2.75 (P=0.0067) for cardiovascular events (7 endpoints) and 3.10 (P=0.022) for coronary events (4 endpoints). With adjustment for cardiovascular risk factors, these hazard ratios were 6.01 (P=0.0003), 2.64 (P=0.0091) and 2.89 (P=0.010), respectively. Analyses unadjusted for blood pressure and antihypertensive treatment produced consistent results. For all fatal plus nonfatal cardiovascular events, the positive predictive value, attributable risk and population-attributable risk associated with TT homozygosity were 21.9, 61.5 and 2.0%, respectively. In conclusion, TT homozygosity at the position -665 in the eNOS promoter predicts adverse outcomes, independent of blood pressure and other risk factors.

Indexed as

AdultBelgiumCardiovascular DiseasesFemaleHumansMaleMiddle AgedNitric Oxide Synthase Type IIIPolymorphism, Single NucleotideWhite PeopleYoung AdultNitric Oxide Synthase Type IIINOS3 protein, human

Identifiers

PMID25102225

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.